ISIN: DE000A12TWS6
WKN: A12TWS
The Issuer hereby gives notice to the Holders of the Notes that it requires a Mandatory Conversion of the Notes pursuant to Sec. 8.1 of the terms and conditions of the Bonds (the “Terms and Conditions”) provided that the Notes have neither been redeemed nor converted or repurchased and cancelled on the Maturity Date (20 July 2016).
The Mandatory Conversion takes place to the Conversion Price pursuant to Sec. 6.1 of the Terms and Conditions. Therefore, the Conversion Price shall be EUR 4.80. The Conversion Price was adapted from EUR 5.00 to EUR 4.80 according to Sec. 12.1 (c) of the Terms and Conditions in July 2015. Each Note shall be converted in such number of Shares that results by dividing the Principal Amount of the Notes to be converted by the applicable Conversion Price in the amount of EUR 4.80. Remaining fractions of shares will be compensated in cash.
The closing price of the shares of the Issuer in XETRA was EUR 7.88 as of 8 June 2016.
A total of 818,658 Notes with a nominal value of EUR 1.00 each were issued, wherefrom 254,811 Notes were not converted in shares as of 8 June 2016. By conversion of 254,811 not yet converted Notes through the Mandatory Conversion, up to 53,085 new shares will be created to the extent Notes are not converted until the Maturity Date (20 July 2016).
The Conversion Procedures are executed according to Sec. 9 of the Terms and Conditions.
Planegg/Martinsried, June 2016
Medigene AG
- The Executive Management Board -
